Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFICACY AND SAFETY OF SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ONCE-WEEKLY IN SUBJECTS WITH OBESITY AND PREDIABETES (VERSION 1.0 DATED 02 MARCH 2021)

Intervention/treatment:
SEMAGLUTIDE
Medical condition:
DIABETES
Protocol code:
NN9536-4734
Control number:
250295
Status:
Closed
Approved:
May 18, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05040971
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Reporting Office (2834)
Organization
Novo Nordisk A/S
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

CHU de Quebec-Universite Laval
Québec, G1V 4G2
Institut universitaire de cardiologie
Québec, G1V 4G5

Alberta

C-endo Diab Endo Clin Calgery
Calgary, Alberta, T2V 4J2
LMC Clin Res Inc. Calgary
Calgary, Alberta, T2H 2G4
University of Calgary
Calgary, Alberta, T2T 5C7
Weight Wise Clinic
Edmonton, Alberta, T6G 2R3

British Columbia

Ocean West Research Clinic
Surrey, British Columbia, V3Z 2N6

New Brunswick

G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7

Nova Scotia

Nova Scotia Hlth Halifax
Halifax, Nova Scotia, B3H 2Y9

Ontario

Centricity Research LMC
Toronto, Ontario, M4G 3E8
Diabetes Heart Research Centre
Toronto, Ontario, M6G 1M2
Dr Anil K Gupta Med Prof Corp
Toronto, Ontario, M9V 4B4
LMC Clinical Research Inc. Oakville
Oakville, Ontario, L6M 1M1
LMC Clin Res Inc. Thornhill
Concord, Ontario, L4K 4M2
LMC ClinRsrh Inc.Brampton
Brampton, Ontario, L6S 0C6
LMC Diabetes & Endocrinology (Barrie)
Barrie, Ontario, L4N 7L3
LMC Endo Ctr (Etobicoke) Ltd
Etobicoke, Ontario, M9R 4E1
LMC Research Inc. Ottawa
Nepean, Ontario, K2J 0V2
Milestone Research
London, Ontario, N5W 6A2
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8M 1K7
Toronto Sleep Institute/MedSleep
Toronto, Ontario, M4P 1P2
Wharton Med Clin Trials
Hamilton, Ontario, L8L 5G8

Quebec

Centre de recherché du CHUS
Sherbrooke, Quebec, J1H 5N4
Centre Medical Acadie
Montreal, Quebec, H4N 2W2
Clinique Medicine Urbaine du Quartier Latin, Inc.
Montreal, Quebec, QC H2L 4E9
Ctr de Med Metab de Lanaudiere
Terrebonne, Quebec, J6X 4P7
LMC Clin Rsrch Inc. (Montreal)
Saint-Laurent, Quebec, H4T 1Z9
Manna Research Mirabel
Mirabel, Quebec, J7J 2K8

Results

See the results from the trial NCT05040971. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?